Neurodegenerative Disorders
15
4
4
3
Key Insights
Highlights
Success Rate
75% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 62/100
6.7%
1 terminated out of 15 trials
75.0%
-11.5% vs benchmark
0%
0 trials in Phase 3/4
0%
0 of 3 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (15)
Elemental 028 Extra Case Studies
Effects of Sabroxy® Supplementation on Insulin Resistance and Cognitive Function in Adults With Mild Cognitive Impairment and Insulin Resistance
Exploratory Clinical Study and Validation of Blood Biomarkers for Alzheimer's Disease
Optimization of Adaptive Rowing Seating
An Innovative Method in SAliva Samples for the Early Differential Diagnosis of High-impact NeuroDegenerative Diseases Through Raman Spectroscopy
Development of IPS from Donated Somatic Cells of Patients with Neurological Diseases
Clinical and Genetic Study of Neurodegenerative Disorders With Cognitive Impairment
A Registered Cohort Study on Color Discrimination Deficit Associated With Neurodegenerative Disorders.
Joint Consultation Between a Neurologist and a Clinical Psychologist
Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions
Tau PET Imaging With 18F-T807(AV1451) in Neurodegenerative Disorders
Bilateral Pallidal Stimulation in Patients With Advanced Parkinson's Disease-LATESTIM
Reproducibility of the 11C-PBR28 PET Signal
Effect of Nicotinamide in Friedreich's Ataxia
COMPARATIVE EFFECTIVENESS OF MCI and DEMENTIA TREATMENTS IN A COMMUNITY-BASED DEMENTIA PRACTICE